A Study to Evaluate the Effect of Food on LY2216684
NCT01389765 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2018-11-13
Summary
This study will evaluate the effect of food on LY2216684. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last dose. Screening is required within 30 days prior to the start of the study.
Conditions
- Depressive Disorder, Major
Interventions
- DRUG
-
LY2216684
Administered orally
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2011-08-31
- Completion
- 2011-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Study in Prevention of Re-emergence of Depression Symptoms
NCT01299272 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY2216684 in Participants With Major Depression Disorder
NCT01370499 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
NCT01263223 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT00840034 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study in Participants With Major Depressive Disorder
NCT01155661 ·Status: COMPLETED ·Phase: PHASE3
-
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT01173601 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
NCT01187407 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot BA Study of New LY03005 vs Pristiq
NCT02988024 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics Study of LY03005
NCT02055300 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
NCT01724112 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2940094 in Major Depressive Disorder
NCT01263236 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY03005 vs Pristiq
NCT03733574 ·Status: COMPLETED ·Phase: PHASE1
-
A Study for Participants With Major Depression
NCT00420004 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
NCT02271412 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
NCT03785652 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine
NCT03290963 ·Status: WITHDRAWN ·Phase: PHASE2
-
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
NCT01217645 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501 ·Status: RECRUITING ·Phase: PHASE3
-
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
NCT05434156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624 ·Status: RECRUITING ·Phase: PHASE3
-
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Treat Major Depressive Disorder (MDD) With a New Medication
NCT02149836 ·Status: COMPLETED ·Phase: PHASE2
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112 ·Status: RECRUITING ·Phase: PHASE3
-
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
NCT00536679 ·Status: COMPLETED ·Phase: PHASE1